Comparison of the Efficacy of Ezetimibe Combination Therapy and High-Intensity Statin Monotherapy in Type 2 Diabetes
CONCLUSION: Adding ezetimibe to a moderate-intensity statin in patients with type 2 diabetes has a greater LDL-C-lowering effect and greater primary prevention of composite outcomes than that of high-intensity statin monotherapy.PMID:38175670 | DOI:10.1210/clinem/dgad714 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - January 4, 2024 Category: Endocrinology Authors: So Young Park Ji Eun Jun In-Kyung Jeong Kyu Jeung Ahn Ho Yeon Chung You-Cheol Hwang Source Type: research
Comparative Efficacy of Rosuvastatin Monotherapy and Rosuvastatin/Ezetimibe Combination Therapy on Insulin Sensitivity and Vascular Inflammatory Response in Patients with Type 2 Diabetes Mellitus
CONCLUSION: Although rosuvastatin/ezetimibe combination therapy had a greater LDL-C reduction effect than rosuvastatin monotherapy, it had no additional effects on insulin sensitivity and vascular inflammatory response. Further studies are needed on the effect of long-term treatment with ezetimibe on insulin sensitivity and vascular inflammatory response.PMID:38173371 | DOI:10.4093/dmj.2022.0402 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - January 4, 2024 Category: Endocrinology Authors: Ji Hye Han Kyong Hye Joung Jun Choul Lee Ok Soon Kim Sorim Choung Ji Min Kim Yea Eun Kang Hyon-Seung Yi Ju Hee Lee Bon Jeong Ku Hyun Jin Kim Source Type: research
Comparative Efficacy of Rosuvastatin Monotherapy and Rosuvastatin/Ezetimibe Combination Therapy on Insulin Sensitivity and Vascular Inflammatory Response in Patients with Type 2 Diabetes Mellitus
CONCLUSION: Although rosuvastatin/ezetimibe combination therapy had a greater LDL-C reduction effect than rosuvastatin monotherapy, it had no additional effects on insulin sensitivity and vascular inflammatory response. Further studies are needed on the effect of long-term treatment with ezetimibe on insulin sensitivity and vascular inflammatory response.PMID:38173371 | PMC:PMC10850282 | DOI:10.4093/dmj.2022.0402 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - January 4, 2024 Category: Endocrinology Authors: Ji Hye Han Kyong Hye Joung Jun Choul Lee Ok Soon Kim Sorim Choung Ji Min Kim Yea Eun Kang Hyon-Seung Yi Ju Hee Lee Bon Jeong Ku Hyun Jin Kim Source Type: research
The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis
CONCLUSION: Response to PCSK9i was minimal in this cohort of patients with HoFH. No patients achieved EAS LDL-C targets, and most failed to reach the EAS-recommended 15% LDL-C reduction for PCSK9i therapy continuation. These results suggest additional LLTs are necessary to achieve LDL-C targets in HoFH.PMID:38169062 | DOI:10.1007/s12325-023-02764-y (Source: Adv Data)
Source: Adv Data - January 3, 2024 Category: Epidemiology Authors: Awad Alshahrani Naji Kholaif Mutaz Al-Khnifsawi Hawazen Zarif Moeber Mahzari Source Type: research
The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis
CONCLUSION: Response to PCSK9i was minimal in this cohort of patients with HoFH. No patients achieved EAS LDL-C targets, and most failed to reach the EAS-recommended 15% LDL-C reduction for PCSK9i therapy continuation. These results suggest additional LLTs are necessary to achieve LDL-C targets in HoFH.PMID:38169062 | DOI:10.1007/s12325-023-02764-y (Source: Adv Data)
Source: Adv Data - January 3, 2024 Category: Epidemiology Authors: Awad Alshahrani Naji Kholaif Mutaz Al-Khnifsawi Hawazen Zarif Moeber Mahzari Source Type: research
The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis
ConclusionResponse to PCSK9i was minimal in this cohort of patients with HoFH. No patients achieved EAS LDL-C targets, and most failed to reach the EAS-recommended 15% LDL-C reduction for PCSK9i therapy continuation. These results suggest additional LLTs are necessary to achieve LDL-C targets in HoFH. (Source: Advances in Therapy)
Source: Advances in Therapy - January 2, 2024 Category: Drugs & Pharmacology Source Type: research
Lipid-Lowering Strategies for Primary Prevention of Coronary Heart Disease in the UK: A Cost-Effectiveness Analysis
ConclusionsLow-density lipoprotein-cholesterol lowering from early ages is a more cost-effective strategy than late intervention and cost effectiveness increased with the increasing lifetime risk of coronary heart disease. (Source: PharmacoEconomics)
Source: PharmacoEconomics - January 1, 2024 Category: Health Management Source Type: research
A New Epoch in Treating Diseases of the Heart
In any medical career, moments stand out when a previous treatment approach is no longer acceptable and a new therapeutic era is ushered in. With the publication of the Diabetes Care and Complications Trial results in 1993,1 intensive diabetes treatment became the standard of care for type 1 diabetes. By showing reductions in both major adverse cardiovascular events (MACE) and total mortality, the 1994 Scandinavian Simvastatin Survival Study (4S)2 initiated a statin arms race, alone and in combination with ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, demonstrating the benefits of progress...
Source: Journal of Clinical Lipidology - January 1, 2024 Category: Lipidology Authors: Jonathan Q Purnell, Samuel A Camacho Tags: Editorial Source Type: research
Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review
CONCLUSION: This meta-analysis showed that 5 mg rosuvastatin/10 mg ezetimibe had largely comparable lipid-modifying efficacy and tolerability as 20 mg rosuvastatin.PMID:38154476 | DOI:10.3349/ymj.2023.0285 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - December 28, 2023 Category: Universities & Medical Training Authors: Yura Kang Jung Mi Park Sang-Hak Lee Source Type: research
Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review
CONCLUSION: This meta-analysis showed that 5 mg rosuvastatin/10 mg ezetimibe had largely comparable lipid-modifying efficacy and tolerability as 20 mg rosuvastatin.PMID:38154476 | DOI:10.3349/ymj.2023.0285 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - December 28, 2023 Category: Universities & Medical Training Authors: Yura Kang Jung Mi Park Sang-Hak Lee Source Type: research
Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review
CONCLUSION: This meta-analysis showed that 5 mg rosuvastatin/10 mg ezetimibe had largely comparable lipid-modifying efficacy and tolerability as 20 mg rosuvastatin.PMID:38154476 | DOI:10.3349/ymj.2023.0285 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - December 28, 2023 Category: Universities & Medical Training Authors: Yura Kang Jung Mi Park Sang-Hak Lee Source Type: research
Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review
CONCLUSION: This meta-analysis showed that 5 mg rosuvastatin/10 mg ezetimibe had largely comparable lipid-modifying efficacy and tolerability as 20 mg rosuvastatin.PMID:38154476 | DOI:10.3349/ymj.2023.0285 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - December 28, 2023 Category: Universities & Medical Training Authors: Yura Kang Jung Mi Park Sang-Hak Lee Source Type: research
Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review
CONCLUSION: This meta-analysis showed that 5 mg rosuvastatin/10 mg ezetimibe had largely comparable lipid-modifying efficacy and tolerability as 20 mg rosuvastatin.PMID:38154476 | DOI:10.3349/ymj.2023.0285 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - December 28, 2023 Category: Universities & Medical Training Authors: Yura Kang Jung Mi Park Sang-Hak Lee Source Type: research
Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review
CONCLUSION: This meta-analysis showed that 5 mg rosuvastatin/10 mg ezetimibe had largely comparable lipid-modifying efficacy and tolerability as 20 mg rosuvastatin.PMID:38154476 | DOI:10.3349/ymj.2023.0285 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - December 28, 2023 Category: Universities & Medical Training Authors: Yura Kang Jung Mi Park Sang-Hak Lee Source Type: research
